Comparison of α-Blocker Monotherapy and α-Blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment of Benign Prostatic Hyperplasia

Author： Joo K-J   Sung W-S   Park S-H   Yang W-J   Kim T-H  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.40, Iss.3, 2012-05, pp. : 899-908

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dutasteride: a novel dual inhibitor of 5α-reductase for benign prostatic hyperplasia

By Djavan Bob   Milani Shirin   Fong Yan Kit  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 2, 2005-02 ,pp. : 311-317

Informa Healthcare

Access to resources Recommend Favorite

A Review on Steroidal 5-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia

By  

Current Medicinal Chemistry, Vol. 18, Iss. 23, 2011-08 ,pp. : 3576-3589

Bentham Science Publishers

Access to resources Recommend Favorite

Alfuzosin: an α1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

By Elhilali Mostafa M  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 5, 2006-04 ,pp. : 583-596

Informa Healthcare

Access to resources Recommend Favorite

The -blocker terazosin is effective in the treatment of benign prostatic hyperplasia

By  

Inpharma, Vol. 1, Iss. 1320, 2002-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Novel inhibitors of 5α-reductase

By Machetti Fabrizio   Guarna Antonio  

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 2, 2002-02 ,pp. : 201-215

Informa Healthcare

Access to resources Recommend Favorite